Split Fed. Circ. Revives GSK's $235M Win Against Teva
The Federal Circuit on Friday revived a $235 million verdict against Teva Pharmaceuticals for inducing infringement of a patent covering GlaxoSmithKline LLC's heart disease drug Coreg. However, the ruling was accompanied...To view the full article, register now.
Already a subscriber? Click here to view full article